No­var­tis poach­es Bris­tol-My­ers/Am­gen vet John Tsai for top drug de­vel­op­ment post in a $9B or­ga­ni­za­tion

No­var­tis CEO Vas Narasimhan has found his re­place­ment as head of their glob­al drug de­vel­op­ment or­ga­ni­za­tion at Am­gen, a big phar­ma part­ner which has led the work on their new mi­graine drug.

John Tsai, the chief med­ical of­fi­cer at Am­gen, is now tak­ing the job Narasimhan left as he moved up to the top suite in Basel. And he’ll be tak­ing one of the most vis­i­ble jobs in drug R&D at a group that spends about $9 bil­lion a year on every­thing from dis­cov­ery to ap­proval — in the top 3 R&D bud­gets on the plan­et with Mer­ck and Roche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER